MDGLMADRIGAL PHARMACEUTICALS, INC.
Pharmaceutical Preparations
- Revenue
- $958M
- 432% YoY
- Operating margin
- -31.3%
- 89% YoY
- EBITDA
- −$299M
- 40% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $48M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired10% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $180M | $958M | 432% |
| Operating income | −$242M | −$294M | −$380M | −$498M | −$300M | 40% |
| Net income | −$242M | −$295M | −$374M | −$466M | −$288M | 38% |
| Operating cash flow | −$184M | −$225M | −$324M | −$456M | −$190M | 58% |
| Capex | $209K | $217K | $1M | $1M | $467K | 68% |
| Stock-based comp | $27M | $32M | $50M | $80M | $98M | 23% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $6M · 24
- Net
- −$6M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 524 | 125 |
| FY2024 | — | — | 278 | 93 |
| FY2023 | — | — | 208 | 94 |
| FY2022 | — | — | 261 | 90 |
| FY2021 | — | — | 76 | 100 |